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Abstract 
Impaired wound healing and ulceration caused by diabetes mellitus,is a significant 
healthcare burden, markedly impairs quality of life for patients, and is the major cause of 
amputation worldwide.  Current experimental approaches used to investigate the complex 
wound healing process often involve cultures of fibroblasts and/or keratinocytes in vitro, 
which can be limited in terms of complexity and capacity, or utilisation of rodent models in 
which the mechanisms of wound repair differ substantively from that in humans.  However, 
advances in tissue engineering, and the discovery of strategies to reprogram adult somatic 
cells to pluripotency, has led to the possibility of developing models of human skin on a 
large scale.   Generation of induced pluripotent stem cells (iPSC) from tissue donated by 
diabetic patients allows the (epi)genetic background of this disease to be studied, and the 
ability to differentiate iPSC to multiple cell types found within skin may facilitate the 
development of more complex skin models; these advances offer key opportunities for 
improving modelling of wound healing in diabetes, and the development of effective 






 The cost of diabetic wounds to the National Health Service is estimated to be around 
£5 billion per year.   
 Rodent models of wound healing fail to recapitulate human wound repair, and in vitro 
systems using human skin cells can be limited in terms of complexity and capacity 
 Reprogramming of cells derived from human donor tissue into pluripotent stem cells 
may allow the development of fully translational skin models of diabetic wound 
healing, facilitating the drug discovery process. 
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Diabetes mellitus is a major global health concern, affecting around 425 million adults 
worldwide, a figure predicted to rise to 629 million people with diabetes by 2045 
(International Diabetes Federation).  Type 1 diabetes mellitus (T1DM) is an auto-immune 
disorder, caused by destruction of insulin-producing pancreatic -cells [reviewed in 1], while 
type 2diabetesmellitus (T2DM) is a polygenic condition characterised by loss of insulin 
secretion and sensitivity, strongly influenced by environmental factors such as obesity [2].   
Single gene disorders, such as neonatal diabetes, Maturity Onset Diabetes of the Young 
(MODY), and mitochondrial mutations (m.3243A>G), can trigger diabetes in younger age 
groups [3].  Diabetes mellitus also presents in a number of rare genetic conditions 
(congenital lipodystrophies [4], Huntington’s disease [5], Friedreich ataxia [6], and Turner 
syndrome [7]), genetic obesity (Prader-Willi syndrome [8], Alstrom syndrome [9] and 
premature aging conditions such as Werner [10] and Hutchinson-Gilford progeria [11] 
syndromes.   It is a complex metabolic disorder, diagnosed clinically by hyperglycaemia [12] 
and associated with chronic inflammation, pro-coagulability, impaired fibrinolysis and 
macro- and microvascular defects, promoting cardiovascular disease (coronary heart 
disease and stroke) [13], renal dysfunction [14, 15], retinopathies [16], neuropathies[16, 17] 
and impairment of wound healing in the extremities [17-20].Foot ulceration is major cause 
of morbidity in type 1 and type 2 diabetes, a significant healthcare burden, and results in 
markedly impaired quality of life for the patient. Globally, the prevalence of diabetic foot 
ulceration in 2017 was 6.3% (95% CI 5.4 to 7.3%) [20]anddiabetes is estimated to cause 
loss of a lower limb (or part thereof) to amputation every 30 seconds worldwide 
(International Diabetes Federation).   
The healing of diabetic woundshas traditionally been investigated using animal models, 
immortalised cell lines and primary cells. Rodents are often used to examine the complex 
healing process in vivo, butdo not fully recapitulate the wound repair process in humans[21, 
22]. Moreover, the requirement forreduction, refinement and replacement (3Rs) of animal 
models, and the severity of the procedures involved,mean that a valid replacement is 
ethically desirable. The use of human primary cells from dermal biopsiesto study wound 
repair in vitro, particularly in 3-dimensional (3-D) organotypic models,has provided valuable 
insights into the wound healing process: for example, the incorporation of diabetic patient-
derived fibroblasts into a 3-D model accurately replicated key features associated with 
chronic ulcersin vitro and in vivo [23].  This article will review these approaches, and 
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highlight recent advances in reprogramming of adult somatic cells to pluripotency, which 
offer exciting opportunities to develop improved models for diabetic wound healing.   
Wound healing: acute and chronic wounds 
Wound healing involves four distinct, but overlapping phases: haemostasis, inflammation, 
proliferation and remodelling (Table 1) [24-26].  Wound clotting is followed by re-
epithelisation at the wound edge around 12-18h post-wounding; concomitantly, a 
granulation tissue is formed by dermal fibroblasts at the wound margin, some of which 
convert to contractile myofibroblasts.  Bone-marrow derived mesenchymal stem cells 
contribute to granulation tissuewhich contains a dense network of capillaries, and 
contraction reduces the surface area requiring re-epithelisation [22-26].  Neutrophils are 
recruited to the site of wounding, to kill microorganisms, followed by macrophages which 
phagocytose cell and matrix debris; these inflammatory cells then either die or leave the 
site of injury, aiding final resolution of the wound.   
Chronic (non-healing) wounds in diabetic patients are characterised by persistent, 
unresolved inflammation, mediated predominantly by infiltrating neutrophils, with a 
significant impairment in local bacterial invasion control.  Diabetic conditions, such as 
inflammation, hyperglycaemia and hyperlipidaemia induce epigenetic changes, promoting 
an inflammatory macrophage phenotype [27] which fails to transition to a pro-healing 
phenotype within the local wound environment [28].   Keratinocytes at the epidermal edge 
are hyper-proliferative, adjacent to an ulcer base which contains exudate and necrotic 
debris; dermal fibroblasts appear senescent and recalcitrant to the migratory stimulant, 
transforming growth factor- (TGF-, and few myofibroblasts are present.  Instead of 
granulation tissue, vessels are surrounded by fibrin cuffs and do not form an effective 
network, rendering the wound poorly vascularised [26, 29].  Advanced glycation end-
products act in concert with inflammatory mediators, and commit fibroblasts and vascular 
cells to apoptosis, contributing to the demise of granulation tissue [30].   
Primary cells, immortalised cell lines and skin explants 
The simplest cell-based model of wound healing in vitro involves culturing a monolayer 
ofprimary fibroblasts, keratinocytes or immortalised cells (e.g.HaCaT keratinocytes) and 
introducing a ‘scrape’ across the surface using a sterile pipette tip: the ‘scratch’ wound 
assay [31, 32, 33]. Migration of cells across the wound can be measured using static or 
time-lapse microscopy, and the expression of proteins involved in inflammation, migration, 
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proliferation, differentiation and remodelling of the extracellular matrix investigated (Table 
1).  Variability can be introduced into the system through changes in oxygen tension, the 
addition of drugs, growth factors or cytokines, or the use of extracellular matrices and 
specialised culture surfaces. These models can also be used to examine differences 
between healing and non-healing wounds, using normal and diabetic cells and altered 
tissue culture environments [23, 34-38]. 
Since the 1970s there has been increasing interest in generating skin constructs which are 
physiologically relevant, capable of mimicking barrier formation, immune and sensory 
functions [39, 40].  Co-cultures of keratinocytes with other cell types, including immune cells 
and dermal fibroblasts, are often used for investigations of wound healing, but these cannot 
entirely replicate the cell-cell and cell-matrix interactions found in a 3-dimensional 
environment.  The use of dermal fibroblasts encapsulated in gel/matrix, combined with 
differentiated keratinocytes forming a 3-D epidermis,often at the air-liquid interface, can 
address some of these limitations, and are useful for modelling changes in keratinocyte 
function, cytokine release after drug treatment, metabolism, irritation and sensitisation, and 
skin aging[23, 41-46].  Tissue-engineered skin products have also been used clinically (e.g. 
Apligraf, Dermagraft) to aid wound repair, particularly to provide barrier function [47, 48]. 
However, the complexity of skin tissue, including the roles of a number of specialised cell 
types such as melanocytes, immune cells (macrophages, Langerhans cells, T cells, 
dendritic cells) and stem cell niches, and of skin appendages (hair follicles), sweat and 
sebaceous glands, obviously cannot be wholly recapitulated in cultures of just keratinocytes 
and/or fibroblasts. 
Vascularisation can be achieved by the addition of endothelial cells, stimulated to form 
capillaries within the dermal environment, and to form a vascular network when supported 
by a suitable scaffold and perfusion system [49].  Other approaches have focused on the 
introduction of melanocytes, to study melanin transfer to keratinocytes, allowing studies of 
photoprotection and acquired (drug-induced) hyper-pigmentation [50], and the inclusion of 
hair follicles, sweat and sebaceous glands, to facilitate study of cosmetics, treatments for 
alopecia and sebo-regulating drugs [40].  The addition of immune cells, innervation of skin 
models, and introduction of the hypodermis (adipose tissue) are desirable for effective drug 
and allergen testing.   
At present, however, it can be difficult to achieve some of these outcomes with primary cells 
derived from human skin biopsies, due to their limited availability and/or growth potential 
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[40, 50].Tissue biopsies are small, making it possible to isolate and expand in culture only 
the most numerous cell types, i.e. dermal fibroblasts and epidermal keratinocytes [50], and 
a negative relationship exists between the extent of expansion of keratinocytes in culture, 
and their longevity in a tissue-engineered epidermis [51, 52].  Minority skin cell populations, 
such as Merkel cells, cannot be greatly expanded in culture [50] and many cell types found 
in skin, such as macrophages, are transient, entering the skin only in response to a 
pathological challenge.  While the use of multiple donors is possible, this approach ignores 
individual responses, and can greatly complicate data analysis [50].Immortalisation of 
primary cell lines can solve some of these problems [32, 33, 53], but the constitutive 
expression of oncogenes can markedly influence cellular phenotype and proliferation rate, 
which maylimit their value for wound healing studies and negate their usefulness clinically.   
Animal models in wound healing studies 
Animal models have been used to replicate the complexity of wound healing in vivo.  Mice 
are the most widely used species for in vivo studies, although other larger species, such as 
pig, more closely mirror human wound healing and are often used in pre-clinical trials [29, 
54].   The epithelial architecture, extracellular matrix, vascular networks and innervation in 
porcine skin are similar to those in human skin, but swine are difficult to house in most 
vivariums, do not lend themselves easily to in vivo imaging experiments and are not fully 
characterized at cellular and physiological levels.  Moreover, the availability of swine-
specific reagents, such as antibodies and growth factors, may be restricted.  Acute wound 
healing in rodents is commonlymonitored following excisional (biopsy punch, surgical 
scissors or laser) or full thickness incisional (scalpel) wounds, made to the foot, thigh or 
back, although considerable variance exists as to the size and number of wounds per 
animal, the tools employed, the presence of occlusive dressings, splints, or non-occlusive 
bandages of varying types, and the use of sutures to close the wound margins [29, 54].   
Chronic wound healing models involve introducing an acute wound, usually in a murine 
model, within the clinical context involved, such as diabetes or ischaemic injury [22, 29] 
Type 1diabetes mellitus can be induced by transgenic breeding (e.g. non-obese diabetic 
(NOD) mice),spontaneous autoimmunity, chemical ablation of pancreatic -cells 
(streptozotocin) or viral infection[55, 56].  High fat feeding or genetic deletion is often used 
to induce a condition resembling T2DM in mice [56]: the most widely used models of T2DM 
are leptin (ob/ob) or leptin receptor (db/db) deficient rodents, which become obese around 
six weeks of age, and subsequently develop T2DM with marked delays in wound healing.  
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Polygenic diabetic strains, such as NONcNZO10/LtJ mice which model human metabolic 
syndrome and obesity-induced diabetes,have also been developed which exhibit defects in 
wound repair [56-58]. 
Despite the common use of animal models to study acute and chronic wound healing, 
physiological differences between species need to be considered [22, 59, 60]. Mouse and 
human skin have markedly different architecture, responsiveness and functionality, due to 
differences in thickness, hair density and appendages; murine skin is also largely devoid of 
sweat glands.  Murine subcutaneous tissue has a thin layer of muscular tissue, the 
panniculus carnosus, which has substantive contractive potential; up to 90% of excisional 
wounds in mice close by contraction.  By contrast, re-epithelization and formation of 
granulation tissue is the predominant mechanism of cutaneous wound healing in human 
dermis [22, 59, 60].  Attempts have been made to address this issue, by splinting excision 
wounds to more closely replicate wound healing in human skin; topical administration of 
platelet-derived growth factor (PDGF), for example, fails to promote closure of a splinted 
wound by re-epithelisation in db/db mice [61], despite its efficacy in othermurine models of 
wound healing.  While wound splinting does allow histologic monitoring of wound bed 
granulation, the healing process still does not fully mimic human wound healing [22, 59, 60].  
Outcomes from wound healing studies in rodents may therefore not be fully translatable to 
humans,possibly explaining the dearth of effective treatments currently available.  
An alternativein vivo approach involves thegeneration of humanised mouse models. 
Shunmugamet al (2015) grafted human skin biopsies from elective abdominoplasty surgery 
onto athymic (nu/nu) mice for three months, before inducing a excision wound into the graft, 
and monitoring wound healing using near infra-red fluorescent imaging [62].   Human skin 
constructs have also been transplanted onto immunodeficient mice: a 3-D matrix, enriched 
with fibrin from human blood plasma was seeded with human fibroblasts to form a dermis, 
before adding an epidermal layer using human keratinocytes [63]; the same group have 
also described a humanised model of delayed wound healing in streptozotocin-induced 
diabetic mice [64].It is clear, however, that all of these approaches to the study of wound 
healing in animals are classified as ‘severe’, likely to cause pain and distress: an ethical 





Induced pluripotent stem cells 
The concept of cell plasticity originates from the groundbreaking work of John Gurdon in the 
1960s [65-67], culminating in the award of the Nobel Prize in Physiology or Medicine (2012) 
jointly with Shinya Yamanaka, more than forty years later;  Yamanaka, together with 
Kazutoshi Takahashi, discovered how mature somatic cells can be reprogrammed to 
become pluripotent stem cells [68-70].  Induced pluripotent stem cells (iPSCs) can be 
derived from individuals with differing genetics, disease conditions or ethnic origins, and 
differentiated to cell types of the three germ layers, revolutionising research and drug 
discovery, and increasing the prospect of personalised regenerative medicine [68-74].   
While early reprogramming strategies used retroviral and lentiviral vectors to deliver the 
transcription factors (e.g. Oct4, Sox2, Klf4, c-Myc) required to reprogram adult somatic cells 
to the pluripotent state [68-71], current reprogramming approaches avoid genomic 
integration [75], by utilising integration-free strategies such as Sendai virus, mRNA, 
microRNA, episomal vectors and non-nucleotide based methods [76-79] (Figure 1).   
Induced pluripotent stem cells are characterised by the ability to self-renew indefinitely, 
stable karyotype, and the potential to differentiate into cell types of the ectoderm, 
mesoderm and endoderm [80-83].  Robust protocols are then needed to differentiate iPSCs 
into cells and tissues of the desired type, characterised by function and/or expression of key 
biomarkers, and the presence of the disease phenotype; disease mechanisms can then be 
investigated, or potential therapeutics tested [80-83].  Age and/or sex matched control 
donor material can be subjected to equivalent reprogramming and differentiation 
procedures; alternatively,isogenic controls can be generated by gene correction of the 
pluripotent cells, using clustered regularly interspace short palindromic repeats (CRISPR)-
.CRISPR associated protein 9 (Cas9), zinc finger nucleases (ZFNs) or transcription 
activator-like effector nuclease (TALEN) systems [84, 85].   
The direct reprogramming and trans-differentiation of somatic cells to specialised cell types, 
including those involved in diabetes and wound healing, has also been described; this 
approach bypasses the pluripotent stage and may therefore prove safer for cell therapy [86-
88].Primitive stem cells, such as hair follicle-associated-pluripotent (HAP) stem cells 
resident in the skin, also have potential to be converted to keratinocytes and melanocytes 
for therapeutic epidermal regeneration without the risk of tumour formation [89].  These 
approaches do not, however, offer the same opportunities for expansion and banking as 
conversion to pluripotency.   
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Pluripotent stem cells and generation of human skin constructs in vitro 
The ability to model the complex interactions of whole tissues and organs using entirely 
human biology is a major goal for tissue engineering and stem cell research, and may 
eventually lead to the production of whole organs for transplantation [90].  Indeed, 
dermatology may be the ideal context for application of iPSC-based therapies, as it is 
readily accessible and easy to monitor, and excision is possible if adverse side effects 
occur [91].  Many of these challenges are also relevant to the development of accurate 
representations of tissue for disease modelling, including skin for wound healing assays.  
The generation of iPSCs from dermal fibroblasts, keratinocytes, melanocytes and dermal 
papilla cells is established, with reprogramming occurring at higher efficiency in 
keratinocytes and melanocytes than in fibroblasts [39, 40, 50].  Moreover, iPSCs have been 
derived from patients with genetic skin disorders, including Type VII collagen-deficient 
Recessive Dystrophic Epidermolysis Bullosa (RDEB), laminin subunit beta 3 (LAMB) gene 
deficient Junctional Epidermolysis Bullosa (JEB), Epidermolysis Bullosa simplex with a 
dominant R125C keratin 14 mutation, and from gene corrected RDEB fibroblasts[92-95].  
Regeneration of human epidermis in vivo using iPSCs is yet to be achieved, but the 
potential of this approach was recently demonstrated by Hirsch et al (2017) who utilised 
autologous transgenic keratinocyte cultures to renew the epidermis in a seven year old 
child suffering from severe JEB [96].  In this case, the epidermis was sustained by a limited 
number of long-lived stem cells or holoclones, self-renewal of which provided progenitor 
cells capable of replacing terminally differentiating keratinocytes [96].   
Notably, it seems that reprogrammed cells retain epigenetic features of the cell type of 
origin (although these disappear on continued passaging) and it has been suggested that 
this residual epigenetic memory may facilitate differentiation back to the corresponding 
original cell type [91, 97-99]. Intriguingly, the process of reprogramming down-regulates 
senescent pathways, elongates telomeres and restores mitochondrial function [100-102] 
effectively ‘rejuvenating’ the cellular phenotype; indeed, ‘rejuvenated’ fibroblasts can also 
be generated from iPS cells derived from very old patients, offering new strategies for 
treatment of chronic wounds in the elderly [91, 102].   
Keratinocytes, fibroblasts and melanocytes have been successfully derived from human 
iPSCs, and iPSCs can be differentiated into immune cells (T-lymphocytes, macrophages 
and dendritic cells), endothelial and smooth muscle cells, Schwann cells and peripheral 
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neurons [39, 40, 50, 103-107] and  iPSC-derived ectodermal precursor cells can contribute 
to hair follicle morphogenesis in vivo [108].  Thus, iPSC-derived skin cells have huge 
potential for skin tissue engineering, and for the development of in vitro skin models for 
healthy and diseased skin, and inacute and chronic wound healing studies.   
Human skin equivalents (HSE) have been generated using iPSC-derived fibroblasts 
and/orkeratinocytes[106-109].  The transcriptome of iPSC-derived keratinocytes proved 
very similar to primary healthy human keratinocytes, while incubation of iPSC-derived 
keratinocytes at an air/liquid interface resulted in epidermal stratification and the 
development of a functional permeability barrier [109].  Itoh et al (2011) generated an in 
vitro 3-D skin equivalent, using a type I collagen matrix to support iPSC-derived fibroblasts 
in the dermis, and iPSC-derived keratinocytes to form an epidermis, and demonstrated 
normal morphology, stratification and terminal differentiation at the air-liquid interface [107]. 
Enriched complexity was achieved by Gledhill et al (2015), by introduction ofiPSC-derived 
melanocytes, responsible for both skin colour and protection against ultraviolet radiation, 
into a 3-D HSE [50].  A collagen I matrix was seeded with iPSC-derived fibroblasts, to 
support iPSC-derived keratinocytes and melanocytes.  The iPSC-derived melanocytes 
localised to the basal layer, extending dendrites into the suprabasal layer of the epidermis, 
and produced melanin which was taken up by iPSC-derived keratinocytes [50]. 
Endothelial and smooth muscle cells, differentiated from human iPSC, cooperate to 
enhance formation of tubular networks in vitro, and in athymic nude mice; co-
transplantation of these cells markedly increased neovascularisation and wound healing in 
a murine dermal wound model [110] compared to primary somatic cells or implantation of 
differentiated endothelial cells alone.   Vascularisation of HSE, comprised of primary 
neonatal dermal fibroblasts and keratinocytes, has also been achieved using iPSC-derived 
endothelial cells [39, 110]. The formerstudy focused on developing an in vitro platform 
capable of recapitulating the cutaneous microcirculation, allowing perfusion and evaluation 
of endothelial barrier function [39].  A 3-D printing technology was used to create the 
desired patterns of vasculature, including inlet-outlet tubes for perfusion, from sacrificial 
microchannels of cross-linked alginate embedded in a dermis consisting of uncrosslinked 
collagen I gel and fibroblasts. Within this context, the diffusion barrier function provided by 
iPSC-derived endothelial cells proved similar to that provided by human umbilical vein 
endothelial cells (HUVECs) [39].   
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Finally, using a rather different approach Zhang et al (2015) developed patient-specific 
mesenchymal stem cells (MSC) from human iPSC, and isolated the exosomes released 
into the extracellular milieu [111].  Exosomes, positive for cluster of differentiation (CD) 9, 
CD63, CD8a, are nano-sized vesicles (30-100nm in diameter) that contain proteins, mRNA 
and micro RNA, and are thought to facilitate wound healing in a paracrine manner.   In this 
study, exosomes derived from iPSC-MSCs enhanced the proliferation and migration of 
fibroblasts and human umbilical vein endothelial cells (HUVECs), increased the secretion of 
collagen and elastin and promoted the formation of tubular networks of endothelial cellsin 
vitro; in a rat wound model, the introduction of iPSC-MSC derived exosomes enhanced 
wound repair, collagen synthesis and angiogenesis [111].   
Thus, the technology exists for use of pluripotent stem cell-based systems in creating 
physiologically relevant and translatable3-D models of human wound healingin vitro,toaid 
the development of novel therapeutics, identifying effective treatments and reducing attrition 
in the later and more costly stages of drug development.  Some barriers exist, however, to 
widespread adoption of these models.  Financial constraints may ultimately be addressed 
by optimisation of cell culture, reprogramming and differentiation protocols; the labour 
intensive nature of the work may also be resolved by high throughput automated 
approaches [112]. Other limitations include variability among iPSC cell lines [113] and 
genomic instability [114, 115].  The establishment of selection criteria for iPSC and iPSC-
derived cells, such as cell-specific markers, assessment of proliferation rate and lifespan, 
and investigation of the transcriptome [112, 113],can help to minimise variability, while 
limiting replication stress during reprogramming, either genetically by targeting checkpoint 
kinase 1 (CHK1) or by using nucleoside supplementation, can help to reduce genomic 
instability [115].   The quality of 3-D skin constructs should also meet key criteria such as 
histological morphology, cell viability and barrier function [106-109].   
Pluripotent stem cells derived from diabetic individuals: disease modelling 
Induced pluripotent stem cells have been derived from individuals with monogenic forms of 
diabetes, and from patients with type 1 and type 2 diabetes mellitus, facilitating research 
into multiple aspects of the complex pathogenesis of these disorders (Table 2), although it 
is clear that the potential for utilisation of these cells in studies of diabetic wound healing is 
yet to be fully realised.The autoimmunity that arises in T1DM results from a complex 
interaction between genetic and immunologic factors [1].  Risk of T1DM progression is 
polygenic, with a large number of genes conferring small risk effects, and a small number of 
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genes having large effects, most particularly the human leukocyte antigens (HLA) DR/DQ 
alleles (e.g. DRB1*03-DQB1*0201 (DR3) or DRB1*04-DQB1*0302 (DR4) [1].   To date, 
genomic wide association studies have identified at least 75 independent genetic loci for 
T2DM although whether all of these variants are causal is not known, and their mechanism 
of action requires further clarification [2, 136, 137].  Further, most of the common variants 
identified confer a relatively low risk of T2DM (odds ratio 1.0 to 1.4) and explain only 10-
15% of the heritability of this disease [136, 137].   These complex inheritance patterns 
highlight the importance of generating iPSCs from diabetic individuals to develop skin 
wound healing models in vitro, although they may effectively negate the possibility of 
generating isogenic controls.   
Epigenetic changes, including those due to an early metabolic insult, are also critical in the 
development of T2D: changes in DNA methylation markers have been identified in blood 
samples and pancreatic islets from T2D patients [137].  At present, it is not clear whether 
these epigenetic changes would be retained during reprogramming to pluripotency, a 
process which induces metabolic changes, including a shift from oxidative to glycolytic 
metabolism of glucose.  However, Harvey et al (2018) recently demonstrated retention of 
metabolic memory in human iPSC: in response to challenge with reduced oxygen 
concentration, iPS cell lines did not respond appropriately, indicating that metabolism had 
not been functionally reprogrammed, failing to recapitulate the metabolic responsiveness of 
embryonic stem cells [138].   
This may pose a significant problem in cell replacement therapy designed to correct defects 
in diabetic patients; for example, the generation of functional insulin-secreting pancreatic -
cells from iPSCs, for potential cell replacement therapy represents a key goal for treatment 
of type 1 and type 2 diabetes [139].Induced pluripotent stem cells have been generated 
from fibroblasts from ulcerated skin of diabetic foot ulcer patients, and compared with those 
from non-ulcerated diabetic skin and from healthy individuals: all of the skin fibroblasts were 
reprogrammed to iPSC with similar efficiencies, indicating that even repair-deficient 
fibroblasts may be useful therapeuticsfor wound healing [134]. Human iPS cells from Type 
1 diabetic patients have also been differentiated into early vascular cells and mature 
endothelial cells which can assemble into 3-D networks when embedded in engineered 
matrices, incorporate into developing zebrafish vasculature, and may prove to be a useful in 
vascular repair for diabetic patients [133].  The challenges currently facing this type of 
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regenerative cell therapy, which are outwith the scope of this review, have been recently 
and comprehensively reviewed [73, 112-115, 140]. 
Arguably, however, retention of the diabetic epigenome, together with the presence of 
genetic variations which increase the risk of T2D, may facilitate the development of 
authentic models, including wound healing, of this disease in vitro.  To date, dermal 
fibroblasts, from patients with the mitochondrial A3243G mutation, associated with maternal 
inherited diabetes and deafness (MIDD) have been used to generate heteroplasmic iPSC 
clones for studies of mitochondrial function [117].  Isogenic iPS clones with either high 
levels of this mutation or undetectable levels of the mutation, from the same individuals; 
complex I activity, mitochondrial respiration and ATP production were compromised in 
some of the mutation-high clones, while those from the mutation-undetectable clones were 
similar to those of iPS cells from healthy subjects [117].   Induced pluripotent stem cell 
clones derived from patients with the same mitochondrial mutation were differentiated into 
retinal pigment epithelial (RPE) cells [141].  The RPE cells contained morphologically 
abnormal mitochondria and melanosomes, and marked functional defects in phagocytosis 
of photoreceptor outer segments, facilitating dissection of the complex tissue-specific 
pathology associated with this mitochondrial mutation [141]. Insulin-resistant iPS cells, 
derived from patients with genetic defects in the insulin receptor, have also been shown to 
exhibit altered mitochondrial size and function, and changes in cellular metabolism [127].  
Thepower of disease modelling using human iPSC is clearly illustrated by Drawnel et al 
(2014), who utilised this approach to develop a patient-specific iPSC model and drug-
screening platform for diabetic cardiomyopathy (DCM) [135].  Firstly, the authors developed 
a surrogate DCM phenotype; iPSC-derived cardiomyocytes (CM), which more closely 
resemble neonatal CMs, were induced to an adult pattern of metabolic activity in two 
differing experimental conditions.  A maturation media, supplemented with insulin and fatty 
acids, which requires the cells to maintain ATP by fatty acid -oxidation, was used to mimic 
the metabolic substrate of adult ventricular CMs, while the re-introduction of glucose, and 
hormonal mediators of diabetes (endothelin-1, cortisol) generated a pattern of gene 
expression associated with hypertrophic stress, and recapitulated the DCM phenotype in 
vitro.   Secondly, iPSC cells were derived from patients with two extreme DCM phenotypes: 
fast progression to cardiovascular disease (within 5y of diagnosis of diabetes) and slow 
progression (no cardiovascular disease despite 15y of T2D).  Dermal fibroblasts were 
reprogrammed to patient-specific iPSC with normal karyotype and differentiation potential; 
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the patient-specific iPSC-derived cardiomyocytes, cultured in the presence of maturation 
media, displayed a basal cardiomyocyte phenotype which corresponded to the clinical 
status of the original donor, in the absence of diabetic stimulus, suggesting retention of 
epigenetic factors.  Suppression of the diabetic phenotype in the environmental model of 
DCM was then successfully employed as a screenable endpoint for small molecules which 
could rescue the phenotype of patient-specific cardiomyocytes [135].  An equivalent 
approach to modelling diabetic wound healing could prove equally insightful and valuable 
therapeutically.   
Concluding remarks:challenges for the future 
The development of robust protocols for reproducible derivation of iPSC from diabetic 
patients, and for differentiation of iPSC into the multiple cell types found within human skin, 
is increasingly being performed using chemically defined and animal-origin free cell culture 
conditions; this is key in limiting batch variability, reducing the use of animal models and 
animal-derived materials, and in improving models of human diabetic wound healing.  
These goals rely on the altruistic donation of tissue from patients, a process facilitated by 
creation of large Biobanks (or Biorepositories) associated with universities, research 
organisations and the National Health Service in the UK.  Biobanks provide ethically 
donated human tissue (normal and diseased), and associated anonymised clinical data, for 
individual studies or to smaller research tissue banks (e.g. GCU Skin Research Tissue 
Bank: www.gcu.ac.uk/hls/research/researchgroups/gcuskinresearchtissuebank/), dedicated 
to the study of human diseases involving complex genetic backgrounds.   The derivation of 
diabetic pluripotent cells, capable of indefinite self-renewal and expansion, and 
differentiation into multiple lineages, may provide new insight into disease mechanisms and 
hold considerable promise for the development of effective therapeutics for treatment of 
chronic wounds in diabetic individuals  
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Table 1: Summary of the stages of wound repair 
Stage Main processes Key molecules  REF 
Haemostasis  Platelet-dependent vasoconstriction 
and fibrin clot formation 
ADP, ATP, GDP, 5-HT 
P2Y12 receptor axis 
Integrin IIb3 
Von Willebrand Factor 
Fibrinogen 
[24] 
Inflammation Release of cytokines 










Macrophages and fibroblasts release 
growth factors 
Migration of fibroblasts and 
proliferation 




Migration, proliferation and 
differentiation of keratinocytes 
Contributions from hair follicle stem 






Fibronectin, type (III) 
collagen, type (I) 
collagen 
Vascular Endothelial 
growth Factor (VEGF) 
 
[22, 25, 26] 
Remodelling Wound fibroblasts adopt a contractile 
myofibroblast phenotype 
Degradation and reorganisation of the 
extracellular matrix 




Type (I) collagen 
 




























Glucokinase (GCK) Maturity Onset 
Diabetes of the 
Young (MODY) 
2 
Defects in insulin 




factor (HNF) 1A 
MODY 3 Defects in insulin 
production 
[118, 119] 
Pancreatic and duodenal 
Homeobox 1 (PDX1)  





Heterozygous PDX1  MODY4 Pathogenesis of MODY4 
and T2DM 
[121] 
HNF1B  MODY5 Pancreatic hypoplasia 








channel, subfamily J, 
member 11 (KCNJ11) 
MODY13 Pathogenesis of MODY13 [124] 
Arginine vasopressin 
(AVP) gene carrying an 
adFND1 causing variant 







Pathogenesis of adFND1 [125] 
Activating germline 
mutation in signal 











Mitochondrial (dys)function [127] 
Loss of paternal gene 
expression in an 
imprinted (epigenetic) 




Willi syndrome and 
associated morbidities 
[128] 




















Defects in adipogenesis 
and pathology of human 
lipodystrophy 
[130] 
- Fulminant type 
1 diabetes 
Cytokine-induced apoptotic 
reactions of -like insulin 
producing cells 
[131] 
- Type 1 diabetes Expression of pancreas-
specific microRNAs 
[132] 
- Type 1 diabetes Autologous vascular 
therapy 
[133] 
- Diabetic foot 
ulcer  
Type 2 diabetes 
Future regenerative 
therapies for diabetic foot 
ulcer 
[134] 
- Type 2 diabetes Disease modelling and 




Figure 1: Modelling of diabetic wound repair using induced pluripotent stem cells   
Patient skin biopsies (diabetic and non-diabetic) can be used to supply frozen tissue or wax 
embedded sections for interrogation by Q-PCR, immunohistochemistry or 
immunofluorescence; alternatively, primary fibroblasts and keratinocytes isolated from the 
dermis and epidermis can be utilised directly in 2- and 3-dimensional studies of wound 
healing, or reprogrammed to pluripotency by delivery (viral, episomal plasmids, mRNA, 
microRNA) of combinations of transcription factors such as octamer binding transcription 
factor 4 (Oct4), Krueppel-like factor-4 (Klf4), sex determining region Y-box 2 (Sox2), Myc 
proto-oncogene protein (c-Myc), lin-28 homolog A (Lin28) or Nanoghomeobox (Nanog).  
Retention of epigenetic ‘memory’ can be assessed from gene expression profiles, 
persistence of donor-cell gene expression and ease of differentiation and both ‘memory’ 
and ‘non-memory’ iPSC which are capable of indefinite self-renewal and expansion can be 
banked; iPSC cell lines can also undergo targeted gene correction by  CRISPR/Cas9, 
TALEN or ZFN systems.   Established and developing protocols can be used to differentiate 
iPSC into a range of cell types found within human skin (fibroblasts, keratinocytes, 
melanocytes),and immune cells (T-lymphocytes, macrophages, dendritic cells and 
neutrophils), endothelial and smooth muscle cells, Schwann cells and peripheral neurons.  
When combined with tissue engineering methodologies, utilisation of skin models derived 
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fromdiabetic iPSC may provide new insight into disease mechanisms, and facilitate the 
development of effective therapeutics for treatment of chronic wounds in diabetic 
individuals.   
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